• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

    10/25/24 8:45:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care
    Get the next $PETQ alert in real time by email

    EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion.

    PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and continues to be operated independently by the Company's executive team.

    "We're pleased to have delivered significant value for PetIQ stockholders through the completion of our transaction with Bansk Group," commented Cord Christensen, Founder, Chairman and CEO of PetIQ. "Through our partnership with Bansk, we look forward to accelerating our mission of providing pet parents convenient access to affordable pet healthcare while accelerating many longer-term growth initiatives for PetIQ's continued success."

    "We're thrilled to partner with Cord and the entire PetIQ team. Together, we look forward to building on the Company's strong momentum as a leading pet health and wellness platform," said Chris Kelly, Senior Partner of Bansk Group. "By leveraging our extensive brand, marketing and operational experience, we see clear runway to expand and enhance PetIQ's capabilities and offerings for pet parents."

    "We believe PetIQ is poised for continued success in the resilient and very attractive pet health and wellness category," said Bart Becht, Senior Partner and Chairman of Bansk Group. "We look forward to supporting the talented PetIQ team in its next phase of growth, through strategic investments in marketing and innovation as well as strategic acquisitions."

    Advisors

    Jefferies LLC served as financial advisor and Cooley LLP served as legal counsel to PetIQ. Davis Polk & Wardwell LLP served as legal counsel to Bansk Group.

    About PetIQ

    PetIQ is a leading pet medication, health and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and veterinary services. The Company's product business engages with pet parents through retail and e-commerce sales channels with its branded and distributed pet medications as well as health and wellness items. PetIQ manufactures and distributes pet products from its world-class facilities in Omaha, Nebraska, Springville, Utah and Daytona Beach, Florida. The Company's veterinarian services offering operates in over 2,600 mobile community clinic locations and wellness centers hosted at retail partners in 39 states. PetIQ believes that pets are an important part of the family and deserve the best products and care we can provide them.

    About Bansk Group

    Founded in 2019, Bansk Group is a New York-based private investment firm focused on investing in and building distinctive consumer brands. The firm partners with differentiated brands across four primary consumer categories: beauty & personal care, consumer health, food & beverage, and household products.

    Over their careers with Bansk and elsewhere, Bansk's tenured group of investors and operators have been involved in more than $30 billion of equity capital investments across more than 40 transactions with some of the most innovative and well-known consumer companies in the world. With extensive investment experience in the consumer products industry, a global network of relationships, and a tested value creation playbook, Bansk seeks to partner with exceptional founders and management teams to drive outsized organic and acquisitive growth and position brands for enduring long-term success in the evolving consumer landscape. www.banskgroup.com

    Contacts

    For PetIQ, Inc.:

    Investors: [email protected] or 208.513.1513

    Media: [email protected] or 407.929.6727

    For Bansk Group:

    Media:

    Woomi Yun / Erik Carlson / Madeline Jones

    Joele Frank, Wilkinson Brimmer Katcher

    +1 (212) 355-4449

    Notice Regarding Forward-Looking Statements

    This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of the transaction with Bansk Group. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Company management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

    Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the definitive proxy statement filed by the Company with the Securities and Exchange Commission on September 16, 2024, in connection with the Agreement, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by the Company from time to time with the Securities and Exchange Commission. These filings, when available, are available on the investor relations section of the Company's website at https://ir.petiq.com/ or on the SEC's website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.



    Primary Logo

    Get the next $PETQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What was the value of the acquisition of PetIQ by Bansk Group?

      PetIQ was acquired by Bansk Group in a deal valued at approximately $1.5 billion.

    • What compensation will PetIQ stockholders receive as part of the acquisition?

      PetIQ stockholders will receive $31.00 in cash for each share held.

    • What impact will the acquisition have on PetIQ's stock trading status?

      After the acquisition, PetIQ shares will no longer be traded on the Nasdaq stock exchange and will be delisted.

    • What are Bansk Group's plans for PetIQ following the acquisition?

      Bansk Group aims to expand and enhance PetIQ's capabilities and offerings for pet parents by leveraging its brand and operational experience.

    • What is Bansk Group's perspective on the pet health and wellness market following the acquisition of PetIQ?

      The acquisition indicates Bansk Group's confidence in the resilience and attractiveness of the pet health and wellness market.

    Recent Analyst Ratings for
    $PETQ

    DatePrice TargetRatingAnalyst
    8/8/2024$30.00 → $31.00Buy → Hold
    Truist
    12/19/2023$22.00Buy
    Jefferies
    9/6/2023$28.00Buy
    Lake Street
    5/13/2022Outperform → Perform
    Oppenheimer
    3/3/2022$32.00 → $29.00Outperform
    Raymond James
    11/30/2021$30.00Buy
    The Benchmark Company
    11/30/2021$30.00Buy
    Benchmark
    11/4/2021$41.00 → $32.00Outperform
    Raymond James
    More analyst ratings

    $PETQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

    EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and co

    10/25/24 8:45:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Results of Special Meeting of Stockholders

    EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. "On behalf of PetIQ's Board of Directors, we are excited to announce stockholders' approval of our proposed transaction with Bansk Group, repre

    10/22/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:31 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:13 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:00:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    SEC Filings

    View All

    SEC Form 15-12G filed by PetIQ Inc.

    15-12G - PetIQ, Inc. (0001668673) (Filer)

    11/4/24 4:27:39 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:19:31 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:10:10 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PetIQ downgraded by Truist with a new price target

    Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously

    8/8/24 6:48:12 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Jefferies initiated coverage on PetIQ with a new price target

    Jefferies initiated coverage of PetIQ with a rating of Buy and set a new price target of $22.00

    12/19/23 6:55:11 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Lake Street initiated coverage on PetIQ with a new price target

    Lake Street initiated coverage of PetIQ with a rating of Buy and set a new price target of $28.00

    9/6/23 9:07:45 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Leadership Updates

    Live Leadership Updates

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Appoints John Pearson to Executive Vice President, Services & Manufactured Products

    EAGLE, Idaho, Aug. 02, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced that John Pearson, who has served as the Company's Senior Vice President, Head of Services since 2022, has been appointed Executive Vice President, Services & Manufactured Products, a newly created role, effective August 2, 2023. In his new role, Pearson will gain responsibility for PetIQ's manufactured product portfolio, inclusive of the Company's sales and marketing teams, while maintaining his current responsibilities for the Services segment. Pearson will continue to report directly to Michael Smith, President and Chief Ope

    8/2/23 8:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Simple Mills Appoints Sheryl O'Loughlin to Board of Directors

    #1 Cookie, Cracker, and Baking Mix Brand in the Natural Channel Taps Industry Veteran to Provide Guidance in Innovation and Sustainability Simple Mills, the company on a mission to advance the holistic health of the planet and its people through delicious, better-for-you foods, today announced the addition of CPG industry veteran, Sheryl O'Loughlin, to its Board of Directors. O'Loughlin is an accomplished entrepreneur, CEO, author, and board member bringing extensive experience leading fast-growing, innovative consumer products companies. In her new role, O'Loughlin will provide strategic counsel and guidance to help support Simple Mills in scaling the company to the next level, creating o

    11/29/22 8:03:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/14/24 6:36:50 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/12/24 5:02:29 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/4/24 11:49:14 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Financials

    Live finance-specific insights

    View All

    PetIQ, Inc. Reports Second Quarter 2024 Financial Results

    Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati

    8/7/24 8:01:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

    EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live

    7/17/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Reports First Quarter 2024 Financial Results

    Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel

    5/8/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care